Breast Cancer
A191901
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
EA1181 (CompassHER2-pCR)
Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
EAZ171
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
S1714
A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
2018-01 (MBMC only) (temporarily closed)
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
NCI 10231 (MBMC only)
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
NRG BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
S1706 (Just in Time trial. See Notes)
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
S1703
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer